Technological watch
Foster appointed marketing partner for Röhm’s Cyrolite portfolio
Foster Corporation’s Distribution business, a company in material solutions for the critical application healthcare market segment, has been appointed as a marketing partner for Röhm’s Cyrolite, Cyrolite MD and XT polymer portfolio of advanced medical acrylic based polymers for the North American healthcare market.
× Foster Distribution will provide sales, technical support, and order fulfilment support from its US locations in Connecticut and Nevada.
Röhm’s medical grade Cyrolite brand is a complete and durable line of acrylic based technologies in the medical material segment and has been in production for more than 50 years. Over its history, the Röhm portfolio has been a resource for applications where transparency, toughness, chemical resistance (alcohol and lipid resistance), gamma/EtO sterilisation, and processability are key specification criteria. In addition, every product in Röhm’s healthcare product portfolio are bio tested to USP Class VI and ISO 10993.
“Cyrolite products have been a mainstay material in the medical device industry for many years,” said Larry Johnson, president, Foster Distribution. “Its clarity is unsurpassed and balanced property matrix makes it a go-to material for many medical device applications that require high-performance at a value-based price point. We couldn’t be more pleased to welcome Röhm into our partnership family. Their product line has more than proven itself over the years and they know the medical industry and its needs and strive to meet those needs.”
“We’re excited to partner with the Foster team which will provide improved distribution of Röhm’s Cyrolite brand to our customers in key medical application segments,” said Thomas Hemler, global segment director, medical moulding compounds, Röhm. “Our Cyrolite product applications range from blood and IV filter housings, fluid connectors, IVD & microfluidic chips - to orthopaedic trays and combination devices for medical device disposables, diagnostics, drug delivery, respiratory & anaesthesiology, and medical packaging.”
Back to Search Results Tags Foster Corporation Rohm Cyrolite distribution medical devices materials
× Foster Distribution will provide sales, technical support, and order fulfilment support from its US locations in Connecticut and Nevada.
Röhm’s medical grade Cyrolite brand is a complete and durable line of acrylic based technologies in the medical material segment and has been in production for more than 50 years. Over its history, the Röhm portfolio has been a resource for applications where transparency, toughness, chemical resistance (alcohol and lipid resistance), gamma/EtO sterilisation, and processability are key specification criteria. In addition, every product in Röhm’s healthcare product portfolio are bio tested to USP Class VI and ISO 10993.
“Cyrolite products have been a mainstay material in the medical device industry for many years,” said Larry Johnson, president, Foster Distribution. “Its clarity is unsurpassed and balanced property matrix makes it a go-to material for many medical device applications that require high-performance at a value-based price point. We couldn’t be more pleased to welcome Röhm into our partnership family. Their product line has more than proven itself over the years and they know the medical industry and its needs and strive to meet those needs.”
“We’re excited to partner with the Foster team which will provide improved distribution of Röhm’s Cyrolite brand to our customers in key medical application segments,” said Thomas Hemler, global segment director, medical moulding compounds, Röhm. “Our Cyrolite product applications range from blood and IV filter housings, fluid connectors, IVD & microfluidic chips - to orthopaedic trays and combination devices for medical device disposables, diagnostics, drug delivery, respiratory & anaesthesiology, and medical packaging.”
Back to Search Results Tags Foster Corporation Rohm Cyrolite distribution medical devices materials
This project has received funding from the Bio Based Industries Joint Undertaking under the European Union’s Horizon 2020 research and innovation programme under grant agreement No 837761.
